All lobbying filings

REGENERON PHARMACEUTICALS, INC

REGENERON PHARMACEUTICALS, INC filed a Q3 report for REGENERON PHARMACEUTICALS, INC on October 20, 2026.

Lobbying for REGENERON PHARMACEUTICALS, INC

All filings by REGENERON PHARMACEUTICALS, INC · Everything REGENERON PHARMACEUTICALS, INC has reported

Filing · LD-2 quarterly report Q3 report

Reporting period

3rd Quarter 2026

July 1 - Sep 30 · Posted Oct 20, 2026

Expenses

$590,000

What this organization spent lobbying with its own staff. Reported using the LDA's own definitions (method A): the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.

Client based in

New York

Official filing document

Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 5

Intellectual property legislation related to biopharmaceutical manufacturers.

Trade (domestic/foreign)

Trade and tariff issues related to corporations; outbound investment restrictions related to biopharmaceutical manufacturers.

Taxation/Internal Revenue Code

Tax and inflation issues related to corporations.

Health Issues

Privacy legislation related to biopharmaceutical manufacturers; Food and Drug Administration and manufacturing issues related to biopharmaceutical manufacturers; National security issues related to biopharmaceutical manufacturers; Public-private contracts for innovation in the biopharmaceutical space; Biosimilar issues related to biopharmaceutical manufacturers.

Medicare/Medicaid

Medicare, Medicaid, and other drug pricing issues relating to biopharmaceutical manufacturers.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.